20.500.12556/DiRROS-25286 Induction chemotherapy and concurrent chemoradiotherapy for larynx preservation in laryngeal and hypopharyngeal cancer To test the hypothesis that clinical tumor response after a single cycle of induction chemotherapy (ICT) can reliably differentiate between chemo-/radiosensitive and resistant tumors in the larynx preservation setting. Patients and methods Treatment consisted of docetaxel/cisplatin/5-fluorouracil (TPF) ICT followed by concurrent chemoradiotherapy (cCRT) with weekly cisplatin. The response of the primary tumor was assessed by transnasal endoscopy after the first ICT cycle. Results 37/39 (95%) patients with laryngeal (46%) or hypopharyngeal (54%) carcinoma responded to one cycle of ICT, and two patients were referred for salvage surgery. Laryngectomy-free survival at 2 and 5 years was 87% and 75%, respectively. The corresponding rates for locoregional control (and also for disease-free survival) were 79% and 70% and for overall survival 92% and 82%. Conclusions Clinical assessment of tumor response to one cycle of TPF ICT serves as a valid and easy-to-use predictor of tumor sensitivity to platinum-based cCRT. induction chemotherapy chemoradiotherapy arynx preservation indukcijska kemoterapija kemoradioterapija ohranitev grla true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2026-01-15 03:48:02 2026-01-16 14:48:30 2026-01-17 04:06:01 0000-00-00 00:00:00 2025 0 Ljubljana 0 Soavtorji: Gaber Plavc, Robert Sifrer, Simona Jereb, Bostjan Lanisnik, Marko Kokalj, Ales Groselj, Cvetka Grasic Kuhar; str. 579-588 no. 4 Vol. 59 Dec. 2025 0000-00-00 Zaloznikova Objavljeno apc 2025-07-21 2025-09-05 2025-12-01 616-006 1318-2099 10.2478/raon-2025-0055 262922755 https://reference-global.com/article/10.2478/raon-2025-0055 1 9edbe095-f1bc-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=38217 https://doi.org/10.2478/raon-2025-0055 1 9ee11c37-f1bc-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=38218 RAZ_Strojan_Primoz_2025.pdf RAZ_Strojan_Primoz_2025.pdf 1 BEA12588AF1F76842D5E5BB5A12A8BF7 961dea1d99db4cc26d7e4ef5de9ce69c4786b236b1705576112f5abf1bf984d7 2cfae132-f2e2-11f0-a15d-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=38363 Onkološki inštitut Ljubljana Univerzitetni klinični center Maribor 0 0 0